SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Boehringer Ingelheim Gives First Dose in Phase 1 Trial of AimedBio-Licensed ADC

The ADC licensed from AimedBio has received its first dose in a Phase 1 clinical trial at Boehringer Ingelheim.

Related stories